Trial Profile
Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sodium nitrite (Primary) ; Isoquercetin
- Indications Kidney disorders
- Focus Pharmacodynamics
- Acronyms NICE
- 11 Aug 2017 Status changed from recruiting to completed.
- 21 Mar 2016 Protocol amended as dose of Isoquercetin changed from 250 mg to 225 mg, Vitamin C has been removed from treatments and dosage form changed from sustained to immediate release, as reported by ClinicalTrials.gov record.
- 21 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.